Clinical trials: Kennedy Disease
Prostatic Neoplasm
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC).
- Trial name
- NCT01337518
- Testing
- EZN-4176
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.
- Trial name
- NCT05241613
- Testing
- AC176
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Accutar Biotechnology Inc
Prostate Cancer
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
The purpose of this study is to determine if a vaccine called pTVG-AR can enhance the participant's immune response against prostate cancer.
- Trial name
- NCT02411786
- Testing
- pTVG-AR, gm-csf
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Partial Edentulism Class II, Dental Implants
Porcelain-fused-to-metal Versus Zirconia Implant- Supported in Mandibular Kennedy Class II
The goal of this randomized clinical trial is to compare biting force and patient satisfaction in three groups. Patients in the control group number one will receive a CoCr removable partial denture, and in the other two groups…
- Conditions
- Partial Edentulism Class II, Dental Implants, Implant
- Trial name
- NCT06150768
- Testing
- Cobalt Chromium Removable Partial Denture, Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture, Implant-Supported Zirconia Fixed Partial Denture.
- Where
- Egypt
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Prostate Cancer
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic…
- Trial name
- NCT06457919
- Testing
- Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the…
- Conditions
- Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
- Trial name
- NCT05669664
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 27 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Cachexia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects
This study is the first administration of GSK2849466 in humans. This will be a single centre, randomized, double-blind, placebo-controlled study, to investigate the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT01696604
- Testing
- GSK2849466
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Trial name
- NCT00685633
- Testing
- bicalutamide, enzastaurin hydrochloride
- Sponsor
- Eastern Cooperative Oncology Group
Cancer of the Prostate
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
This is an investigator-initiated phase II single arm trial, combining neoadjuvant apalutamide (ARN509) with radical prostatectomy, in the treatment of D'Amico intermediate to high risk organ-confined prostate cancer.
- Trial name
- NCT03124433
- Testing
- Apalutamide
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Cachexia
Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
GSK2881078 is a selective androgen receptor modulator (SARM) that is being evaluated for effects on muscle growth and strength in subjects with muscle wasting to improve their physical function.
- Trial name
- NCT02567773
- Testing
- GSK2881078, Itraconazole
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HER2 Amplified, Advanced Breast Cancer
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.
- Conditions
- HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
- Trial name
- NCT02091960
- Testing
- Enzalutamide, Trastuzumab
- Where
- 39 sites in United States, Belgium and 4 more
- Volunteers
- 103 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Androgen Insensitivity Syndrome, Metabolic Parameters in AIS, CAIS, PAIS and MAIS
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity
Background: Androgen effects in humans are usually (but not always) mediated by the androgen receptor which is coded for by the androgen receptor gene (AR gene).
- Conditions
- Androgen Insensitivity Syndrome, Metabolic Parameters in AIS, CAIS, PAIS and MAIS, Tumor Formation in AIS, CAIS, PAIS and MAIS, Sexual Function AIS, CAIS, PAIS and MAIS
- Trial name
- NCT04708431
- Where
- United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Metastatic Prostate Cancer
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
- Trial name
- ARX517 (NCT04662580)
- Testing
- ARX517, Apalutamide, Abiraterone acetate
- Where
- 12 sites in United States
- Volunteers
- 183 people
- Sponsor
- Janssen Research & Development, LLC
Androgen Receptor Gene Overexpression, Normal Responders
Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response
AR is a steroid hormone receptor that regulates various genes' expression and affects cellular proliferation and differentiation.
- Conditions
- Androgen Receptor Gene Overexpression, Normal Responders, Poor Ovarian Response, Bologna Criteria
- Trial name
- NCT03433768
- Testing
- Real time PCR
- Volunteers
- 67 people
- Sponsor
- Aristotle University Of Thessaloniki
Libido, Receptors, Androgen
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
It is known that with increasing age sexual desire is declining in women. Decreasing levels of androgens are believed to have an influence, but cannot explain the loss of libido completely.
- Conditions
- Libido, Receptors, Androgen, Polymorphism, Genetic, Androgen Effect
- Trial name
- CAG-Libido (NCT01977313)
- Where
- Switzerland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Adverse Effect of Oral Contraceptives, Initial Encounter
The Effect of Hormonal Contraception on Female
The aim- To evaluate the impact of combined oral contraceptives on women's psychosexual, metabolic, blood coagulation, hormonal and genetic measures.
- Trial name
- HORMCONTRA (NCT01852786)
- Testing
- Contraceptives, Oral, Combined, Controls
- Where
- Lithuania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Lithuanian University of Health Sciences
Muscular Atrophy, Spinal
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
This was a phase IV Open-label, single-arm, single-dose, multicenter study, to evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with SMA with bi-allelic mutations in…
- Trial name
- OFELIA (NCT05073133)
- Testing
- OAV101
- Where
- 5 sites in Argentina, Brazil
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Bulbo-Spinal Atrophy, X-Linked, Kennedy Disease
MRI in Patients With Kennedy Disease
Kennedy disease is an inherited neuromuscular disorder that is characterized by progressive muscle wasting and weakness. It typically starts with muscle spasms and tremors in the arms, followed by muscle weakness and atrophy of…
- Trial name
- NCT02501395
- Testing
- No intervention, observational
- Where
- Denmark
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Androgenetic Alopecia
Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Previous studies of finasteride treatment in women with hair loss have failed to show positive results, yet, some women have responded anecdotally.
- Trial name
- NCT01052870
- Testing
- Finasteride
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- HairDx, LLC